Global Longlife Hospital and Research Ltd.

43.29 ▼0%

16 April 2024, 04:01:00 PM

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Industry Icon Hospital & Healthcare Services Compare with Industry peers
Website http://www.globalhospital.co.in
Market Cap 45.45 Cr.
Enterprise Value(EV) 56.76 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 1.74 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 24.87 Trailing Twelve Months Ending 2023-03
Industry PE 66.40 Trailing Twelve Months Ending 2023-03
Book Value / Share 58.94 Trailing Twelve Months Ending 2023-03
Price to Book Value 0.73 Calculated using Price: 43.29
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 1.05 Cr. 10,500,000 Shares
FaceValue 10
About Global Longlife Hospital and Research Ltd.
The company provides health care services. The company offers Oncology, Ophthalmology, Cardiology, Dermatology, Gynecology, Spine Surgery, Plastic Surgery, Ultrasound, Microbiology, Dialysis, and Physiotherapy among other healthcare services. Global Longlife Hospital is certified by the National Accreditation Board for Hospitals and Healthcare Providers (NABH Accredited).

Global Longlife Hospital and Research Ltd. Delivery

Delivered Qty
Traded Qty

Global Longlife Hospital and Research Ltd. Performance

1 Day
1 Week
+0.67%
1 Month
+0.67%
3 Month
-21.29%
6 Month
-3.80%
1 Year
-7.80%
2 Year
5 Year
10 Year

Global Longlife Hospital and Research Ltd. Fundamental Ratios

5 years 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 11.05 -7.23 18.94 29.65 4.82
Return on Capital Employed (%) 12.09 3.69 13.49 29.36 6.69
Return on Assets (%) 3.4 -2.19 5.72 11.1 3.47

Global Longlife Hospital and Research Ltd. Balance Sheet

Particulars 6 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 12 11 14 17 64 65
Non Curr. Liab. 15 14 9 1 2 0
Curr. Liab. 13 13 10 14 8 12
Minority Int.
Equity & Liab. 40 39 33 31 74 77
Non Curr. Assets 25 23 18 17 38 40
Curr. Assets 15 16 12 11 34 37
Misc. Exp. not W/O 4 3 2
Total Assets 40 39 33 31 74 77

Global Longlife Hospital and Research Ltd. Profit and Loss

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Net Sales 35 34 33 33 24
Other Income 0 0 0 0 0
Total Income 35 34 33 33 24
Total Expenditure -28 -30 -27 -25 -19
PBIDT 7 4 6 8 4
Interest -2 -2 -2 -2 0
Depreciation -2 -2 -1 -1 -1
Taxation -1 0 0 -2 -1
Exceptional Items
PAT 1 -1 2 4 2
Adjusted EPS 3 5 2

Global Longlife Hospital and Research Ltd. Cash Flow

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 5 4 7 9 -40
Cash Fr. Inv. 0 0 0 0 -2
Cash Fr. Finan. -5 -3 -7 -10 46
Net Change 0 1 0 0 3
Cash & Cash Eqvt 0 1 0 0 4

Global Longlife Hospital and Research Ltd. Shareholding Pattern

7 Qtrs 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%)
Promoter 54.29 54.29 54.29 54.29 54.29 54.29 54.29
Public 45.71 45.71 45.71 45.71 45.71 45.71 45.71
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Global Longlife Hospital and Research Ltd. Announcements

Wed, 17 Apr 2024
Compliances-Reg.24(A)-Annual Secretarial Compliance
Clarification for non applicability of Regulation 24(A) of SEBI (LODR) Regulations 2015 for the year ended March 31 2024
Wed, 17 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended March 31 2024
Fri, 12 Apr 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th April 2024
The Board of Directors of the Company in its meeting held today accorded its consent to sale/dispose or otherwise deal with the all assets of the Company together with all specified tangible or intangible assets in relation to the Undertaking on a slump sale basis on an as is where is basis or substantial parts or in any other manner to the potential investors/ buyers/ third-parties as the Board may deem fit in the overall interest of all the stakeholders. The above decision was taken to make the Company asset light and carry out the hospital business on lease/ profit sharing basis.Pursuant to Section 180(1)(a) of the Companies Act 2013 and Regulation 37A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the approval of the members of the Company for the aforementioned matter shall be sought in ensuing General meeting of the Company which will be held on Tuesday 14th May 2024.

Global Longlife Hospital and Research Ltd. Technical Scans

Tue, 16 Apr 2024
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
Opening at Low Opening at Low
Opening at High for 3 days Opening at High for 3 days
Opening at High for 2 Days Opening at High for 2 Days

Global Longlife Hospital and Research Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 364,015.10 1,523.80 -0.9%
Cipla Ltd. 108,808.58 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. 99,408.67 5,959.10 -1.5%
Divi's Laboratories Ltd. 98,683.96 3,717.35 -1.3%
Mankind Pharma Ltd. 96,037.07 2,397.40 +5.0%
Zydus Lifesciences Ltd. 94,213.69 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. 87,250.69 6,107.00 -3.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 40.87 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-12 29.34 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.01 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-12 71.36 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-12 55.61 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.68 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 110.54 6,107.00 -3.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.83 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-12 4.20 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.70 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-12 7.57 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-12 10.81 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.00 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 12.92 6,107.00 -3.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 0.02 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,107.00 -3.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 12.85 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,107.00 -3.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 12.85 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,107.00 -3.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,107.00 -3.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,107.00 -3.6%

Global Longlife Hospital and Research Ltd. FAQ's

What is Global Longlife Hosp share price?

Can I buy Global Longlife Hosp shares now?

What is the Market Cap of Global Longlife Hosp?

What are the key metrics to analyse Global Longlife Hosp?

What is the 52 Week High and Low of Global Longlife Hosp?